Two years to generate a contracted preclinical study on their claimed block buster prospect. At this rate we can expect the drug will take another 10 years to full development. But not to fret, the senior staff will be able to maintain their lucrative posts with little prospect of attrition, all sustained with shareholders passivity. No concerted pressure, no demands from any of us except to sell at our frustration. The share price tells all. I too am steadily selling from a once very strong holding.
Ann: NNZ-2591 positive effects in Phelan-McDermid syndrome model, page-7
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.65 |
Change
-0.310(1.48%) |
Mkt cap ! $2.676B | |||
| Open | High | Low | Value | Volume |
| $21.00 | $21.21 | $20.65 | $1.140M | 54.30K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 150 | $20.65 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.70 | 541 | 11 |
View Market Depth
| Last trade - 10.32am 30/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$20.64 |
Change
-0.310 ( 2.00 %) |
||||
| Open | High | Low | Volume | ||
| $20.97 | $21.15 | $20.62 | 16108 | ||
| Last updated 10.52am 30/05/2024 ? | |||||
| NEU (ASX) Chart |